vs

Side-by-side financial comparison of Align Technology (ALGN) and Astrana Health, Inc. (ASTH). Click either name above to swap in a different company.

Align Technology is the larger business by last-quarter revenue ($1.0B vs $950.5M, roughly 1.1× Astrana Health, Inc.). Align Technology runs the higher net margin — 10.8% vs 0.7%, a 10.2% gap on every dollar of revenue. On growth, Astrana Health, Inc. posted the faster year-over-year revenue change (42.9% vs 6.2%). Over the past eight quarters, Astrana Health, Inc.'s revenue compounded faster (53.3% CAGR vs 0.6%).

Align Technology, Inc., a medical device company, designs, manufactures, and markets Invisalign clear aligners and iTero intraoral scanners and services for orthodontists and general practitioner dentists, and restorative and aesthetic dentistry. It operates in two segments, Clear Aligner; and Scanners and Services. The Clear Aligner segment consists of comprehensive products, including Invisalign comprehensive treatment that addresses the orthodontic needs of teenage patients, such as mandib...

Astrana Health, Inc. is a U.S.-based value-based healthcare services provider that primarily serves Medicare-eligible senior populations across the United States. It offers in-home primary care, chronic disease management, and care coordination services, aiming to improve patient health outcomes and reduce unnecessary medical costs.

ALGN vs ASTH — Head-to-Head

Bigger by revenue
ALGN
ALGN
1.1× larger
ALGN
$1.0B
$950.5M
ASTH
Growing faster (revenue YoY)
ASTH
ASTH
+36.7% gap
ASTH
42.9%
6.2%
ALGN
Higher net margin
ALGN
ALGN
10.2% more per $
ALGN
10.8%
0.7%
ASTH
Faster 2-yr revenue CAGR
ASTH
ASTH
Annualised
ASTH
53.3%
0.6%
ALGN

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
ALGN
ALGN
ASTH
ASTH
Revenue
$1.0B
$950.5M
Net Profit
$112.8M
$6.6M
Gross Margin
70.8%
Operating Margin
13.6%
1.9%
Net Margin
10.8%
0.7%
Revenue YoY
6.2%
42.9%
Net Profit YoY
21.0%
184.4%
EPS (diluted)
$1.57
$0.12

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ALGN
ALGN
ASTH
ASTH
Q1 26
$1.0B
Q4 25
$1.0B
$950.5M
Q3 25
$995.7M
$956.0M
Q2 25
$1.0B
$654.8M
Q1 25
$979.3M
$620.4M
Q4 24
$995.2M
$665.2M
Q3 24
$977.9M
$478.7M
Q2 24
$1.0B
$486.3M
Net Profit
ALGN
ALGN
ASTH
ASTH
Q1 26
$112.8M
Q4 25
$135.8M
$6.6M
Q3 25
$56.8M
$373.0K
Q2 25
$124.6M
$9.4M
Q1 25
$93.2M
$6.7M
Q4 24
$103.8M
$-7.8M
Q3 24
$116.0M
$16.1M
Q2 24
$96.6M
$19.2M
Gross Margin
ALGN
ALGN
ASTH
ASTH
Q1 26
70.8%
Q4 25
65.3%
Q3 25
64.2%
Q2 25
69.9%
Q1 25
69.5%
Q4 24
70.0%
Q3 24
69.7%
Q2 24
70.3%
Operating Margin
ALGN
ALGN
ASTH
ASTH
Q1 26
13.6%
Q4 25
14.8%
1.9%
Q3 25
9.7%
2.0%
Q2 25
16.1%
3.1%
Q1 25
13.4%
3.3%
Q4 24
14.5%
0.1%
Q3 24
16.6%
5.9%
Q2 24
14.3%
6.2%
Net Margin
ALGN
ALGN
ASTH
ASTH
Q1 26
10.8%
Q4 25
13.0%
0.7%
Q3 25
5.7%
0.0%
Q2 25
12.3%
1.4%
Q1 25
9.5%
1.1%
Q4 24
10.4%
-1.2%
Q3 24
11.9%
3.4%
Q2 24
9.4%
3.9%
EPS (diluted)
ALGN
ALGN
ASTH
ASTH
Q1 26
$1.57
Q4 25
$1.88
$0.12
Q3 25
$0.78
$0.01
Q2 25
$1.72
$0.19
Q1 25
$1.27
$0.14
Q4 24
$1.40
$-0.14
Q3 24
$1.55
$0.33
Q2 24
$1.28
$0.40

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ALGN
ALGN
ASTH
ASTH
Cash + ST InvestmentsLiquidity on hand
$1.1B
$429.5M
Total DebtLower is stronger
Stockholders' EquityBook value
$4.1B
$779.3M
Total Assets
$6.3B
$2.2B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ALGN
ALGN
ASTH
ASTH
Q1 26
$1.1B
Q4 25
$1.1B
$429.5M
Q3 25
$1.0B
$463.4M
Q2 25
$901.2M
$342.1M
Q1 25
$873.0M
$260.9M
Q4 24
$1.0B
$290.8M
Q3 24
$1.0B
$350.3M
Q2 24
$761.4M
$327.7M
Stockholders' Equity
ALGN
ALGN
ASTH
ASTH
Q1 26
$4.1B
Q4 25
$4.0B
$779.3M
Q3 25
$4.0B
$775.5M
Q2 25
$3.9B
$765.5M
Q1 25
$3.8B
$745.4M
Q4 24
$3.9B
$712.7M
Q3 24
$3.9B
$704.6M
Q2 24
$3.8B
$678.9M
Total Assets
ALGN
ALGN
ASTH
ASTH
Q1 26
$6.3B
Q4 25
$6.2B
$2.2B
Q3 25
$6.2B
$2.2B
Q2 25
$6.2B
$1.4B
Q1 25
$6.1B
$1.3B
Q4 24
$6.2B
$1.4B
Q3 24
$6.4B
$1.3B
Q2 24
$6.2B
$1.3B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ALGN
ALGN
ASTH
ASTH
Operating Cash FlowLast quarter
$151.0M
$-2.9M
Free Cash FlowOCF − Capex
$-6.0M
FCF MarginFCF / Revenue
-0.6%
Capex IntensityCapex / Revenue
0.3%
Cash ConversionOCF / Net Profit
1.34×
-0.44×
TTM Free Cash FlowTrailing 4 quarters
$104.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ALGN
ALGN
ASTH
ASTH
Q1 26
$151.0M
Q4 25
$223.2M
$-2.9M
Q3 25
$188.7M
$10.0M
Q2 25
$128.7M
$90.9M
Q1 25
$52.7M
$16.6M
Q4 24
$286.1M
$-10.9M
Q3 24
$263.7M
$34.0M
Q2 24
$159.8M
$23.2M
Free Cash Flow
ALGN
ALGN
ASTH
ASTH
Q1 26
Q4 25
$187.3M
$-6.0M
Q3 25
$169.0M
$7.4M
Q2 25
$107.2M
$89.5M
Q1 25
$27.4M
$13.6M
Q4 24
$263.1M
$-13.5M
Q3 24
$233.9M
$31.7M
Q2 24
$106.4M
$20.4M
FCF Margin
ALGN
ALGN
ASTH
ASTH
Q1 26
Q4 25
17.9%
-0.6%
Q3 25
17.0%
0.8%
Q2 25
10.6%
13.7%
Q1 25
2.8%
2.2%
Q4 24
26.4%
-2.0%
Q3 24
23.9%
6.6%
Q2 24
10.3%
4.2%
Capex Intensity
ALGN
ALGN
ASTH
ASTH
Q1 26
Q4 25
3.4%
0.3%
Q3 25
2.0%
0.3%
Q2 25
2.1%
0.2%
Q1 25
2.6%
0.5%
Q4 24
2.3%
0.4%
Q3 24
3.0%
0.5%
Q2 24
5.2%
0.6%
Cash Conversion
ALGN
ALGN
ASTH
ASTH
Q1 26
1.34×
Q4 25
1.64×
-0.44×
Q3 25
3.33×
26.69×
Q2 25
1.03×
9.65×
Q1 25
0.57×
2.48×
Q4 24
2.76×
Q3 24
2.27×
2.11×
Q2 24
1.66×
1.21×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ALGN
ALGN

Clear Aligner$856.0M82%
CAM Services$184.1M18%

ASTH
ASTH

Medicare$542.4M57%
Commercial$99.1M10%
Care Delivery$92.1M10%
Care Enablement$78.9M8%
Other Third Parties$58.0M6%
Health Care Patient Service$39.8M4%
Health Care Other$25.5M3%
Other$12.1M1%
Management Service$10.3M1%

Related Comparisons